<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-5547-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SPINRAZA 2.4 mg/ml Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NUSINERSEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intrathecal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        394762.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Italia S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Italia S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biogen Idec B.V-Natherland
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M09AX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Spinraza contains the active substance <em>nusinersen </em>which belongs to a group of medicines known as <em>antisense oligonucleotides</em>. Spinraza is used to treat a genetic disease called <em>spinal muscular atrophy </em>(SMA).</p><p>&nbsp;</p><p><strong>Spinal muscular atrophy </strong>is caused by a shortage of a protein called <em>survival motor neuron </em>(SMN) in the body. This results in the loss of nerve cells in the spine, leading to weakness of the muscles in the shoulders, hips, thighs and upper back. It may also weaken the muscles used for breathing and swallowing.</p><p>&nbsp;</p><p>Spinraza works by helping the body to produce more of the SMN protein that people with SMA are lacking. This reduces the loss of nerve cells and so may improve muscle strength.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you or your child are <strong>allergic to nusinersen </strong>or any of the other ingredients of this medicine</p><p>(listed in section 6).</p><p>&nbsp;</p><p>If you are not sure, talk to your doctor or nurse before you or your child are given Spinraza.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>There is a risk of side effects occuring after Spinraza is given by a lumbar puncture procedure (see section 3). This can include headaches, vomiting and back pain. There may also be difficulties with giving a medicine by this method in very young patients and those with scoliosis (twisted and curved</p><p>spine).</p><p>&nbsp;</p><p>Other products that are in the same group of medicines as Spinraza have been shown to affect the cells in the blood which help clotting. Before you or your child are given Spinraza your doctor may decide to do a blood test to check that you or your child&rsquo;s blood can clot properly. This may not be required every time you or your child are given Spinraza.</p><p>&nbsp;</p><p>Other products that are in the same group of medicines as Spinraza have been shown to affect the kidneys. &nbsp;Before you or your child are given Spinraza your doctor may decide to do a urine test to check that you or your child&rsquo;s kidneys are working normally. This may not be required every time you or your child are given Spinraza.</p><p>&nbsp;</p><p>There have been a small number of reports of patients developing hydrocephalus (a build-up of too much fluid around the brain) after Spinraza is given. Some of these patients had needed to have a device called a ventriculo-peritoneal shunt implanted to treat the hydrocephalus. If you notice any symptoms of increase in head size, decreased consciousness, persistent nausea, vomiting or headache; or other symptoms that cause you concern, please inform you or your child&rsquo;s doctor to seek necessary treatment. The benefits and risks of continuing Spinraza whilst having a &quot;ventriculo-peritoneal shunt&quot; in place are not known at present.</p><p>&nbsp;</p><p>Talk to your doctor before you or your child are given Spinraza.</p><p><strong>&nbsp;</strong></p><p><strong>Ot</strong><strong>h</strong><strong>e</strong><strong>r medicines and Spinraza</strong></p><p>Tell your doctor if you or your child are taking, have recently taken any, or might take any other</p><p>medicines in future.</p><p>&nbsp;</p><p><strong>P</strong><strong>r</strong><strong>egnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask</p><p>your doctor for advice before being given this medicine. It is preferable to avoid the use of Spinraza during pregnancy and breast-feeding.</p><p>&nbsp;</p><p><strong>D</strong><strong>riving and using machines</strong></p><p>Spinraza has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Spinraza contains a small amount of sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per 5 ml vial, that is to say essentially &lsquo;sodium-free&rsquo; and can be used by people on a sodium-restricted diet.</p><p>&nbsp;</p><p><strong>Spinraza contains a small amount of potassium</strong></p><p>This medicine contains potassium, less than 1 mmol (39 mg) per 5 ml vial, i.e essentially &lsquo;potassium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The usual dose of Spinraza is 12 mg.</p><p>&nbsp;</p><p>Spinraza is given;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On the first day of treatment, day 0</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then around day 14, day 28 and day 63</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Then once every 4 months.</p><p>&nbsp;</p><p>Spinraza is given by injection into the lower back. This injection, called a lumbar puncture, is done by inserting a needle into the space around the spinal cord. This will be done by a doctor experienced in doing lumbar punctures. You or your child may also be given a medicine to make you relax or sleep during the procedure.</p><p>&nbsp;</p><p><strong>H</strong><strong>o</strong><strong>w long to use Spinraza</strong></p><p>Your doctor will tell you how long you or your child need to receive Spinraza. Don&rsquo;t stop treatment with Spinraza unless your doctor tells you to.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you or your child misses an injection</strong></p><p>If you or your child miss a dose of Spinraza, speak with your doctor so that Spinraza can be given as</p><p>soon as possible.</p><p>&nbsp;</p><p>If you have any questions about how Spinraza is given, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Side effects related to the lumbar puncture may occur while Spinraza is being given or</p><p>afterwards. The majority of these side effects are reported within 72 hours of the procedure.</p><p>&nbsp;</p><p><u>V</u><u>e</u><u>ry</u><u> </u><u>common (may affect more than 1 in 10 people)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&nbsp;</p><p><u>N</u><u>ot known (frequency cannot be estimated from the available data)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious infection related to lumbar puncture (e.g. meningitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrocephalus (a build-up of too much fluid around the brain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Meningitis not caused by an infection (inflammation of the membrane around the spinal cord and brain, which may present as neck stiffness, headache, fever, nausea and vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity (an allergic or allergic-like reaction that may include swelling of your face, lips or tongue, rash, or itching)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arachnoiditis (an inflammation of a membrane surrounding the brain and spinal cord), which can cause pain in the lower back, or pain, numbness or weakness in the legs</p><p>&nbsp;</p><p><strong>R</strong><strong>eporting of side effects</strong></p><p><strong>I</strong><strong>f you or your child get any side effects, talk to your doctor or nurse</strong>. This includes any possible</p><p>side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>United Arab Emirates:</strong></p><p>Pharmacovigilance &amp; Medical Device Section</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>P.O.Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Dubai</p><p>&nbsp;</p><p>- <strong>Oman</strong></p><p>&nbsp;</p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Tel: 22357687 / 22357686</p><p>Fax: 22358489</p><p>Email: &nbsp;pharma-vigil@moh.gov.om</p><p>Website: www.moh.gov.om</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot; &nbsp;<strong><em>Other GCC States:</em></strong></p><p>&nbsp;</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the vial and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>If no refrigeration is available, Spinraza may be stored in its original carton, protected from light at or below 30&deg;C for up to 14 days.</p><p>&nbsp;</p><p>Unopened vials of Spinraza can be removed from and returned to the refrigerator if necessary. If removed from the original carton, the total time out of refrigeration should not exceed 30 hours, at a temperature that does not exceed 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is nusinersen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 5 ml vial contains nusinersen sodium equivalent to 12 mg nusinersen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each ml contains 2.4 mg of nusinersen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium dihydrogen phosphate dihydrate, disodium phosphate, sodium chloride (see section 2 &ldquo;Spinraza contains a small amount of sodium&rdquo;), potassium chloride (see section 2 &ldquo;Spinraza contains a small amount of potassium&rdquo;), calcium chloride dihydrate, magnesium chloride hexahydrate, sodium hydroxide, hydrochloric acid, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Spinraza is a clear colourless solution for injection. 
Each carton of Spinraza contains one vial.
Each vial is for single use.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>B</strong><strong>ulk manufacturer</strong></p><p>Patheon Italia S.p.A., 2 Trav. SX. Via</p><p>Morolense, 5 Ferentino 03013, Italy</p><p>&nbsp;</p><p><strong>Manufacturer (Final batch Releaser):</strong></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aug 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي سبينرازا على المادة الفعالة نوسينرسين، التي تنتمي إلى مجموعة من الأدوية المعروفة باسم أنتيسنس أوليجونوكلوتيدات. ويستخدم سبينرازا في علاج المرض الجيني المسمى <em>ضمور العضلات الشوكي</em> (SMA).</p><p>يحدث ضمور العضلات الشوكي نتيجة حدوث نقص في بروتين يسمى عصبون البقاء الحركي (SMN) في الجسم، وينتج عن ذلك فقدان الخلايا العصبية في العمود الفقري، مما يؤدي إلى ضعف العضلات في الكتفين والوركين والفخذين وأعلى الظهر. وقد يُسبب أيضًا ضعف العضلات المستخدمة في التنفس والبلع.</p><p>يعمل سبينرازا من خلال مساعدة الجسم على إنتاج المزيد من بروتين عصبون البقاء الحركي، الذي يفتقر إليه الأشخاص الذين يعانون من مرض ضمور العضلات الشوكي. وهذا يقلل من فقدان الخلايا العصبية، وبالتالي قد يحسّن من قوة العضلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>يجب عدم إعطاء سبينرازا في حالة:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أنت أو طفلك تعانيان من <strong>حساسية لمادة</strong> <strong>النوسينرسين</strong>، أو أيٍّ من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من ذلك، استشر طبيبك أو الممرضة قبل أن تتناول سبينرازا أنت أو طفلك.</p><p>&nbsp;</p><p>التحذيرات والاحتياطات</p><p dir="RTL">هناك بعض الآثار الجانبية التي قد تحدث بعد تناول سبينرازا، من خلال إجراء البزل القطني (انظر القسم 3), والتي قد تشمل الصداع والقيء وآلام الظهر. وقد تكون هناك صعوبات أيضًا في إعطاء الدواء بهذه الطريقة للمرضى الصغار جدًّا والذين يعانون من انحراف العمود الفقري (العمود الفقري الملتوي والمنحني).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد تبيّن أن المنتجات الأخرى التي في نفس مجموعة الأدوية التي يوجد بها سبينرازا، تؤثر على الخلايا الموجودة في الدم والتي تساعد على تجلّط الدم. وقد يقرر طبيبك أن يقوم بإجراء اختبار للدم، قبل أن يصف سبينرازا لك أو لطفلك؛ للتأكد من أن دمك أو دم طفلك يتجلط بشكلٍ سليم. وقد لا يكون هذا مطلوبًا في كل مرة يتم فيها وصف سبينرازا لك أو لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتبيّن كذلك أن المنتجات الأخرى التي في نفس مجموعة الأدوية التي يوجد بها سبينرازا، تؤثر على الكلى. وقد يقرر طبيبك أن يقوم بإجراء اختبار للبول، قبل أن يصف سبينرازا لك أو لطفلك؛ للتأكد من أن كلْيتك أو كلْية طفلك تعمل بصورة طبيعية. وقد لا يكون ذلك مطلوبًا في كل مرة يتم فيها وصف سبينرازا لك أو لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تمّ الإبلاغ عن إصابة عددٍ قليلٍّ من المرضى بالاستسقاء الدماغي (تجمع كمية كبيرة جدًا من السوائل حول المخ) بعد العلاج باستخدام سبينرازا. ولقد احتاج بعض هؤلاء المرضى جهازًا يسمى التحويلة البطينية الصفاقية يتم زرعه لعلاج الاستسقاء الدماغي. إذا لاحظت أيّ أعراض مثل زيادة حجم الرأس أو إنخفاض في الوعي أو الغثيان المستمر أو القيء أو الصداع&nbsp; أو غيرها من الأعراض التي تسبب لك القلق، يرجى إبلاغ طبيبك أو طبيب طفلك لإعطائك العلاج المناسب. بالنسبة لفوائد ومخاطر الاستمرار في استخدام سبينرازا أثناء وجود جهاز التحويلة البطينية الصفاقية فهي غير معروفة حتى الآن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك، قبل أن يتم وصف سبينرازا لك أو لطفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سبينرازا والمنتجات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>الأخرى</strong></p><p dir="RTL">أخبِر طبيبك إذا كنت أنت أو طفلك تتناولان، أو تناولتما مؤخرًا، أو قد تتناولان في المستقبل أي أدويةٍ أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية&nbsp; </strong></p><p dir="RTL">إذا كنتِ حاملًا، أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنكِ حامل، أو تخططين للحمل-استشيري طبيبكِ قبل تناول هذا الدواء. ولكن من الأفضل تَجَنُّب استخدام سبينرازا أثناء الحمل والرضاعة الطبيعية.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات </strong></p><p dir="RTL">ليس لسبينرازا أي تأثير يُذكر على القدرة على قيادة السيارات واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سبينرازا على كمية صغيرة من الصوديوم.&nbsp; </strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) في كل قارورة حجمها 5 ملل، بمعنى أنه &quot;خالٍ من الصوديوم&quot; بشكلٍ أساسي، ويمكن أن يستخدمه الأشخاص الذين يتَّبِعون نظامًا غذائيًّا قليل الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سبينرازا على كمية صغيرة من البوتاسيوم.&nbsp; </strong></p><p dir="RTL">يحتوي هذا الدواء على البوتاسيوم، أقل من 1 مليمول (39 ملغ) في كل قارورة حجمها 5 ملل، أي إنه &quot;خالٍ من البوتاسيوم&quot; بشكلٍ أساسي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة المعتادة من سبينرازا هي 12 ملغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم تناول سبينرازا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم الأول من العلاج، اليوم 0.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم حوالي اليوم الـ 14، واليوم الـ 28، واليوم الـ 63.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثم مرة كل 4 أشهر.</p><p>&nbsp;</p><p dir="RTL">يتم إعطاء سبينرازا عن طريق الحقن أسفل الظهر. وتسمى طريقة الحقن هذه البزل القطني، وهي تتم عن طريق إدخال إبرة في المساحة الموجودة حول الحبل الشوكي، ويتم ذلك عن طريق طبيب من ذوي الخبرة في إجراء البزل القطني. كما يمكن إعطاء دواء لك أو لطفلك؛ لكي يجعلك تسترخي أو تنام أثناء هذا الإجراء.</p><p>&nbsp;</p><p>ما هي مدة استخدام سبينرازا؟</p><p dir="RTL">سيخبرك طبيبك عن المدة التي تحتاج خلالها أنت أو طفلك لتلقي العلاج بسبينرازا. لا تتوقف عن العلاج بسبينرازا ما لم يخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا فاتتك أنت أو طفلك إحدى الحقن</strong></p><p dir="RTL">إذا فاتتك أنت أو طفلك إحدى جرعات سبينرازا، فتحدّث مع طبيبك لكي يتم إعطاؤك سبينرازا في أقرب وقتٍ ممكن.&nbsp;</p><p dir="RTL">إذا كان لديك أي تساؤلات حول كيفية أخذ سبينرازا، فاسأل طبيبك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث آثار جانبية تتعلق بالبزل القطني أثناء إعطاء سبينرازا، أو بعد إعطائها. وغالبًا ما تظهر معظم تلك الآثار الجانبية في غضون 72 ساعة من الإجراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية الشائعة جدًّا (التي قد تصيب أكثر من شخصٍ واحدٍ من كل 10 أشخاص)</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير معروف</u>ة<u> (لا يمكن تقدير تكرارها من البيانات المتاحة)</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى خطيرة تتعلق بالبزل القطني (مثل التهاب السحايا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستسقاء الدماغي (تجمع الكثير جدا من السوائل حول المخ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب السحايا غير الناتج عن عدوى (التهاب الأغشية المحيطة بالحبل الشوكي والمخ، والذي قد يظهر في صورة تصلب في الرقبة وصداع وحمى وغثيان وقيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية (رد الفعل التحسسي أو شبه التحسسي الذي قد يتضمن تورم الوجه أو الشفتين أو اللسان أو الطفح الجلدي أو الحكة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العنكبوتية )التهاب غشاء يحيط بالدماغ والحبل الشوكي(الذي يمكن أن يسبب ألمًا في أسفل الظهر أو ألمًا أو تنميلًا أو ضعفًا في الساقين.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p dir="RTL"><strong>إذا تعرّض طفلك لأي آثار جانبية، فاستشر الطبيب أو الممرضة</strong>. ويتضمن ذلك أية آثار جانبية غير مُدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني. إن إبلاغك عن الآثار الجانبية يمكن أن يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أيٍّ من الآثار الجانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong><em>الإمارات العربية المتحدة</em></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">اليقظة الدوائية</p><p dir="RTL">إدارة العقاقير</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">ص. ب: 1853 دبي</p><p dir="RTL">الإمارات العربية المتحدة</p><p dir="RTL">الخط الساخن: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong><em>عُمان</em></strong></p><p dir="RTL">دائرة التيقظ والمعلومات الدوائية&nbsp;</p><p dir="RTL">المديرية العامة للصيدلة والرقابة الدوائية&nbsp;</p><p dir="RTL">وزارة الصحة، سلطنة عمان&nbsp;</p><p dir="RTL">هاتف: 22357686/22357687</p><p dir="RTL">فاكس: 22358489</p><p dir="RTL">البريد الإلكتروني:&nbsp;pharma-vigil@moh.gov.om</p><p dir="RTL">الموقع الإلكتروني:www.moh.gov.om</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أيٍّ من الآثار الجانبية:</strong></p><ul><li dir="RTL"><strong>المملكة العربية السعودية:</strong></li></ul><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ والسلامة الدوائية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصالات الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">دول مجلس التعاون الخليجي الأخرى:</p><p dir="RTL">يُرجى الاتصال بالسلطة المختصة ذات الصلة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدوَّن على القارورة والعلبة بعد كلمة &quot;تاريخ الانتهاء&quot;. تاريخ الانتهاء يشير إلى اليوم الأخير من الشهر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (ما بين درجة حرارة 2 و8 درجات مئوية). لا تقم بتجميده.</p><p dir="RTL">احفظ القارورة في العلبة الخارجية لحمايتها من الضوء.</p><p dir="RTL">في حالة عدم توافر التبريد، يمكن تخزين سبينرازا في العلبة الأصلية، لحمايتها من الضوء عند أو أقل من 30 درجة مئوية، لمدة تصل إلى 14 يومًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إخراج القوارير غير المفتوحة من سبينرازا من الثلاجة، وإعادتها إليها عند الحاجة. إذا تم إخراج القارورة من العلبة الأصلية, يجب ألا تتجاوز مدة بقاء القارورة خارج الثلاجة مدة 30 ساعة، في درجة حرارة لا تزيد عن 25 درجة مئوية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي النوسينرسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي كل قارورة حجمها 5 ملل على كمية من نوسينرسين الصوديوم عادل 12 ملغ نوسينرسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل ملل على 2.4 ملغ من نوسينرسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي فوسفات الصوديوم ثنائي الهيدروجين ثنائي الهيدرات، وفوسفات ثنائي الصوديوم، وكلوريد الصوديوم (راجع القسم 2 &quot;يحتوي سبينرازا على كمية صغيرة من الصوديوم&quot;)، وكلوريد البوتاسيوم (راجع القسم 2 &quot;يحتوي سبينرازا على كمية صغيرة من البوتاسيوم&quot;)، وكلوريد الكالسيوم ثنائي الهيدرات، وكلوريد المغنيسيوم هيكساهيدريت، وهيدروكسيد الصوديوم، وحمض الهيدروكلوريك، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سبينرازا هو محلول للحقن، شفاف بلا لون.</p><p dir="RTL">تحتوي كل عبوة من سبينرازا على قارورة واحدة.</p><p dir="RTL">تُستخدم كل قارورة مرة واحدة فقط.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مصنع الشكل الصيدلاني</strong></p><p>Patheon Italia S.p.A., 2 Trav. SX. Via Morolense, 5 Ferentino 03013, Italy</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع المسؤول عن تحرير الصنف</strong></p><p dir="RTL">Biogen Netherlands B.V.</p><p dir="RTL">Prins Mauritslaan 13</p><p dir="RTL">1171 LP Badhoevedorp</p><p dir="RTL">The Netherlands</p><p>&nbsp;</p><p><strong>مالك</strong><strong> </strong><strong>رخصة</strong><strong> </strong><strong>التسويق</strong></p><p dir="RTL">Biogen Netherlands B.V.</p><p dir="RTL">Prins Mauritslaan 13</p><p dir="RTL">1171 LP Badhoevedorp</p><p dir="RTL">The Netherlands</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اغسطس 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Spinraza 12 mg solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml vial contains nusinersen sodium equivalent to 12 mg nusinersen.
Each ml contains 2.4 mg of nusinersen.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection. 

Clear and colourless solution with pH of approximately 7.2.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Spinraza should only be initiated by a physician with experience in the management of spinal muscular atrophy (SMA).</p><p>&nbsp;</p><p>The decision to treat should be based on an individualised expert evaluation of the expected benefits</p><p>of treatment for that individual, balanced against the potential risk of treatment with Spinraza. Patients with profound hypotonia and respiratory failure at birth, where Spinraza has not been studied, may not</p><p>experience a clinically meaningful benefit due to severe survival motor neuron (SMN) protein deficiency.</p><p><s><u>&nbsp;</u></s></p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dosage is 12 mg (5 ml) per administration.</p><p>Spinraza treatment should be initiated as early as possible after diagnosis with 4 loading doses on</p><p>Days 0, 14, 28 and 63. A maintenance dose should be administered once every 4 months thereafter.</p><p><em>&nbsp;</em></p><p><em>Duration of treatment</em></p><p>Information on long term efficacy of this medicinal product is not available. The need for</p><p>continuation of therapy should be reviewed regularly and considered on an individual basis depending</p><p>on the patient&rsquo;s clinical presentation and response to the therapy.</p><p>&nbsp;</p><p><em>Missed or delayed doses</em></p><p>If a loading or a maintenance dose is delayed or missed Spinraza should be administered according to the schedule in Table 1 below.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table </strong><!--[if supportFields]><u><span
style='mso-ansi-language:EN-US;mso-bidi-font-weight:bold'><span
style='mso-element:field-begin'></span></span></u><b><span style='mso-ansi-language:
EN-US'><span style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC </span></b><u><span
style='mso-ansi-language:EN-US;mso-bidi-font-weight:bold'><span
style='mso-element:field-separator'></span></span></u><![endif]--><strong>1</strong><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--><strong>: Recommendations for delayed or missed dose</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Delayed or missed dose &nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Timing of Dosing Administration</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Loading dose</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the delayed or missed loading dose as soon as possible with at least 14 days between doses; continue with subsequent doses on the prescribed intervals from the last dose.</p><p>&nbsp;</p><p>e.g. if the third loading dose is administered 30 days late at Day 58 (instead of the original schedule at Day 28), then the fourth loading dose should be administered 35 days later at Day 93 (instead of the original schedule at Day 63) with a maintenance dose 4 months thereafter.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose </strong></p></td><td style="vertical-align:top"><p><strong>Timing of Dosing Administration </strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;&nbsp;4 to &lt;&nbsp;8 months&nbsp;from last dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the delayed maintenance dose as soon as possible;&nbsp;then</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The next maintenance dose per the original scheduled date, as long as these two doses are administered at least 14 days apart*;</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;8 to &lt;&nbsp;16 months from last dose</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the missed dose as soon as possible and then the next dose 14 days later*;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;16 to &lt;&nbsp;40 months from last dose</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the missed dose as soon as possible and then the next dose 14 days later, followed by a third dose 14 days later*;</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;40 months from last dose&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the entire loading regimen on the prescribed intervals (Days 0, 14, 28 and 63)*;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*then subsequently to the above recommendations, a maintenance dose 4 months after the last dose should be administered and repeated every 4 months.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Nusinersen has not been studied in patients with renal impairment. The safety and efficacy in patients</p><p>with renal impairment has not been established and they should be closely observed.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Nusinersen has not been studied in patients with hepatic impairment. Nusinersen is not metabolised via the cytochrome P450 enzyme system in the liver, therefore dose adjustment is unlikely to be required in patients with hepatic impairment (see sections 4.5 and 5.2).</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Spinraza is for intrathecal use by lumbar puncture.</p><p>Treatment should be administered by health care professionals experienced in performing lumbar punctures.</p><p>&nbsp;</p><p>Spinraza is administered as an intrathecal bolus injection over 1 to 3 minutes, using a spinal anaesthesia needle. The injection must not be administered in areas of the skin where there are signs of infection or inflammation. It is recommended that the volume of cerebral spinal fluid (CSF), equivalent to the volume of Spinraza to be injected, is removed prior to administration of Spinraza.</p><p>&nbsp;</p><p>Sedation may be required to administer Spinraza, as indicated by the clinical condition of the patient. Ultrasound (or other imaging techniques) may be considered to guide intrathecal administration of Spinraza, particularly in younger patients and in patients with scoliosis; see instructions for use in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Lumbar puncture procedure</u></p><p><u>&nbsp;</u></p><p>There is a risk of adverse reactions occurring as part of the lumbar puncture procedure (e.g. headache, back pain, vomiting; see section 4.8). Potential difficulties with this route of administration may be seen in very young patients and those with scoliosis. The use of ultrasound or other imaging techniques to assist with intrathecal administration of Spinraza, can be considered at the physician&rsquo;s discretion.</p><p>&nbsp;</p><p><u>Thrombocytopenia and coagulation abnormalities</u></p><p><u>&nbsp;</u></p><p>Thrombocytopenia and coagulation abnormalities, including acute severe thrombocytopenia, have been observed after administration of other subcutaneously or intravenously administered antisense oligonucleotides. If clinically indicated, platelet and coagulation laboratory testing is recommended prior to administration of Spinraza.</p><p>&nbsp;</p><p><u>Renal toxicity</u></p><p><u>&nbsp;</u></p><p>Renal toxicity has been observed after administration of other subcutaneously and intravenously administered antisense oligonucleotides. If clinically indicated, urine protein testing (preferably using a first morning urine specimen) is recommended. For persistent elevated urinary protein, further evaluation should be considered.</p><p>&nbsp;</p><p><u>Hydrocephalus</u></p><p>There have been reports of communicating hydrocephalus not related to meningitis or bleeding in patients treated with nusinersen in the post-marketing setting. Some patients were implanted with a ventriculo-peritoneal shunt. In patients with decreased consciousness, an evaluation for hydrocephalus should be considered. The benefits-and risks of nusinersen treatment in patients with a ventriculo-peritoneal shunt are unknown at present and the maintenance of treatment needs to be carefully considered.</p><p>&nbsp;</p><p><u>Excipients </u></p><p>&nbsp;</p><p><em>Sodium</em></p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per 5 ml vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><em>Potassium</em></p><p>&nbsp;</p><p>This medicinal product contains potassium, less than 1 mmol (39 mg) per 5 ml vial, i.e. essentially &lsquo;potassium-free&rsquo;.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No interaction studies have been performed. <em>In vitro </em>studies indicated that nusinersen is not an inducer or inhibitor of CYP450 mediated metabolism. <em>In vitro </em>studies indicate that the likelihood for interactions with nusinersen due to competition for plasma protein binding, or competition with or inhibition of transporters is low.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of child bearing potential</u></p><p>&nbsp;</p><p>There are no data from clinical studies on the use of nusinersen during pregnancy in humans.</p><p>The benefit of treatment with nusinersen versus potential risk should be discussed with women of childbearing age or women who become pregnant during therapy.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no or limited amount of data from the use of nusinersen in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of nusinersen during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether nusinersen/metabolites are excreted in human milk.</p><p>&nbsp;</p><p>A risk to the newborn/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from nusinersen therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>In toxicity studies in animals no effects on male or female fertility were observed (see section 5.3). There are no data available on the potential effects on fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Nusinersen has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p><u>&nbsp;</u></p><p>The most common adverse reactions (ADRs) associated with the administration of Spinraza were headache, vomiting and back pain.</p><p>The safety of Spinraza was assessed in clinical trials based on two Phase 3 clinical studies in infants (CS3B) and children (CS4) with SMA, together with one Phase 2 study in infants and children with SMA (CS7) and open-label studies including pre-symptomatic infants (CS5) genetically diagnosed with SMA and infants and children with SMA. Study CS11 enrolled infantile and later-onset patients including those who had completed studies CS3B, CS4 and CS12. Of the 352 patients who received Spinraza up to a maximum of 5 years, 271patients received treatment for at least 1 year.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions </u></p><p><u>&nbsp;</u></p><p><u>The safety assessment of Spinraza is based on data from patients from clinical trials and from post-marketing surveillance. The ADRs associated with Spinraza administration are summarised in Table 2.</u></p><p><u>&nbsp;</u></p><p>The assessment of undesirable effects is based on the following frequency data:</p><p>Very common (&ge;&nbsp;1/10)</p><p>Not known (cannot be estimated from the available data)</p><p><u>&nbsp;</u></p><p><strong>Table&nbsp;2: Adverse reactions related to Spinraza administration</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>MedDRA System Organ Class</p></td><td rowspan="2" style="vertical-align:top"><p>Adverse reaction</p></td><td rowspan="2" style="vertical-align:top"><p>Frequency category</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Meningitis</p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>** </sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache<sup>*</sup></p><p>Aseptic meningitis</p></td><td style="vertical-align:top"><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp; Not known</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Vomiting<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Back pain<sup>*</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td>&nbsp;</td></tr></tbody></table><p><sup>*</sup>Adverse reactions considered related to the lumbar puncture procedure. These reactions can be considered manifestations of post‑lumbar puncture syndrome.&nbsp; These adverse reactions were reported in CS4 (later onset SMA) with an incidence at least 5% higher in patients treated with Spinraza (n=84) compared to Sham control.<sup> </sup></p><p><sup>**</sup>e.g. angiodema, urticaria and rash.</p><p><u>&nbsp;</u></p><p><u>Clinical trial experience:Clinical Trial in Infantile-Onset SMA (Study 1)</u></p><p><u>In Study 1, baseline disease characteristics were largely similar in the Spinraza-treated patients and sham-control patients except that Spinraza-treated patients at baseline had a higher percentage compared to sham-control patients of paradoxical breathing (89% vs 66%), pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%), and requirement for respiratory support (26% vs 15%).</u></p><p><u>The most common adverse reactions that occurred in at least 20% of Spinraza-treated patients and occurred at least 5% more frequently than in control patients were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in Spinraza-treated patients (18%) than in control patients (10%). Because patients in Study 1 were infants, adverse reactions that are verbally reported could not be assessed in this study.</u></p><p><strong>Table 3: Adverse reactions that occurred in at least 5% of Spinraza patients and occurred at least 5% more frequently or at least 2 times as frequently than in control patients with infantile-onset SMA (Study 1)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Adverse Reactions </u></p></td><td style="vertical-align:top"><p><u>Spinraza 12 mg<sup>1 </sup>N = 80 % </u></p></td><td style="vertical-align:top"><p><u>Sham-Procedure Control N = 41 % </u></p></td></tr><tr><td><p><u>Lower respiratory infection<sup>2</sup> </u></p></td><td style="vertical-align:top"><p><u>55 </u></p></td><td style="vertical-align:top"><p><u>37 </u></p></td></tr><tr><td><p><u>Constipation </u></p></td><td><p><u>35 </u></p></td><td><p><u>22 </u></p></td></tr><tr><td><p><u>Teething </u></p></td><td><p><u>18 </u></p></td><td><p><u>7 </u></p></td></tr><tr><td><p><u>Urinary tract infection </u></p></td><td><p><u>9 </u></p></td><td><p><u>0 </u></p></td></tr><tr><td><p><u>Upper respiratory tract congestion </u></p></td><td style="vertical-align:top"><p><u>8 </u></p></td><td style="vertical-align:top"><p><u>2 </u></p></td></tr><tr><td><p><u>Ear infection </u></p></td><td><p><u>6 </u></p></td><td><p><u>2 </u></p></td></tr><tr><td><p><u>Flatulence </u></p></td><td><p><u>5 </u></p></td><td><p><u>2 </u></p></td></tr><tr><td><p><u>Decreased weight </u></p></td><td><p><u>5 </u></p></td><td><p><u>2 </u></p></td></tr></tbody></table><p><u><sup>1</sup></u><u> Loading doses followed by 12 mg (5 mL) once every 4 months </u></p><p><u><sup>2 </sup></u><u>Includes adenovirus infection, bronchiolitis, bronchitis, bronchitis viral, corona virus infection, Influenza, lower respiratory tract infection, lower respiratory tract infection viral, lung infection, parainfluenzae virus infection, pneumonia, pneumonia bacterial, pneumonia influenzal, pneumonia moraxella, pneumonia parainfluenzae viral, pneumonia pneumococcal, pneumonia pseudomonal, pneumonia respiratory syncytial viral, pneumonia viral, and respiratory syncytial virus bronchiolitis.</u></p><p><u>In an open-label clinical study in infants with symptomatic SMA, severe hyponatremia was reported in a patient treated with Spinraza requiring salt supplementation for 14 months.</u></p><p><u>Cases of rash were reported in patients treated with Spinraza. One patient, 8 months after starting Spinraza treatment, developed painless red macular lesions on the forearm, leg, and foot over an 8-week period. The lesions ulcerated and scabbed over within 4 weeks, and resolved over several months. A second patient developed red macular skin lesions on the cheek and hand ten months after the start of Spinraza treatment, which resolved over 3 months. Both cases continued to receive Spinraza and had spontaneous resolution of the rash. Spinraza may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of Spinraza on growth would be reversible with cessation of treatment.</u></p><p><u>Clinical Trial in Later-Onset SMA (Study 2)</u></p><p><u>In Study 2, baseline disease characteristics were largely similar in the Spinraza-treated patients and sham-control patients except for the proportion of Spinraza-treated patients who had ever achieved the ability to stand without support (13% vs 29%) or walk with support (24% vs 33%).</u></p><p><u>The most common adverse reactions that occurred in at least 20% of spinraza-treated patients and occurred at least 5% more frequently than in control patients were pyrexia, headache, vomiting, and back pain.</u></p><p><strong>Table 4: Adverse reactions that occurred in at least 5% of Spinraza patients and occurred at least 5% more frequently or at least 2 times as frequently than in control patients with later-onset SMA (Study 2)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:641px"><tbody><tr><td style="vertical-align:top"><p><u>Adverse Reactions</u></p></td><td style="vertical-align:top"><p><u>SPINRAZA 12 mg<sup>1</sup> N=84 % </u></p></td><td style="vertical-align:top"><p><u>Sham-Procedure Control N=42 % </u></p></td></tr><tr><td><p><u>Pyrexia </u></p></td><td><p><u>43 </u></p></td><td><p><u>36 </u></p></td></tr><tr><td><p><u>Headache </u></p></td><td><p><u>29 </u></p></td><td><p><u>7 </u></p></td></tr><tr><td><p><u>Vomiting </u></p></td><td><p><u>29 </u></p></td><td><p><u>12 </u></p></td></tr><tr><td><p><u>Back pain </u></p></td><td><p><u>25 </u></p></td><td><p><u>0 </u></p></td></tr><tr><td><p><u>Epistaxis </u></p></td><td><p><u>7 </u></p></td><td><p><u>0 </u></p></td></tr><tr><td><p><u>Fall </u></p></td><td><p><u>5 </u></p></td><td><p><u>0 </u></p></td></tr><tr><td><p><u>Respiratory tract congestion </u></p></td><td><p><u>5 </u></p></td><td><p><u>2 </u></p></td></tr><tr><td><p><u>Seasonal allergy </u></p></td><td><p><u>5 </u></p></td><td><p><u>2 </u></p></td></tr></tbody></table><p><u><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 </sup></u><u>Loading doses followed by 12 mg (5 mL) once every 6 months</u></p><p><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Post-lumbar puncture syndrome has also been observed after administration of Spinraza.</u></p><p>Events of communicating hydrocephalus have been observed in the post-marketing setting (see section 4.4).</p><p><u>&nbsp;</u></p><p><sup>&nbsp;</sup></p><p><u>Description of selected adverse reactions</u></p><p><sup>&nbsp;</sup></p><p>Adverse reactions associated with the administration of Spinraza by lumbar puncture have been observed. The majority of these are reported within 72 hours of the procedure. The incidence and severity of these events were consistent with events expected to occur with lumbar puncture. No serious complications of lumbar puncture, such as serious infections, have been observed in the clinical trials of Spinraza.</p><p>&nbsp;</p><p>Some adverse reactions commonly associated with lumbar puncture (e.g. headache and back pain) could not be assessed in the infant population exposed to Spinraza due to the limited communication appropriate for that age group.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>The immunogenic response to nusinersen was determined in 346 patients with baseline and</p><p>post-baseline plasma samples evaluated for anti-drug antibodies (ADA). Overall, the incidence of ADAs was low, with 15 (4%) patients classified as ADA positive overall, of which 4 had a transient response, 5 had a persistent response, and 6 patients had responses which could not be classified as transient or persistent at the time of data cut off. The impact of immunogenicity on safety was not formally analysed as the number of patients with ADAs was low. However, individual safety data for the treatment-emergent ADA-positive cases were reviewed, and no adverse events (AEs) of interest were identified.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><strong>To report any side effect (s):</strong></p><p><u>&nbsp;</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No cases of overdose associated with adverse reactions were reported in clinical studies.</p><p>&nbsp;</p><p>In the event of an overdose, supportive medical care should be provided including consulting with a healthcare professional and close observation of the clinical status of the patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other drugs for disorders of the musculo-skeletal system, ATC code: M09AX07</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Nusinersen is an antisense oligonucleotide (ASO) which increases the proportion of exon 7 inclusion in survival motor neuron 2 (SMN2) messenger ribonucleic acid (mRNA) transcripts by binding to an intronic splice silencing site (ISS-N1) found in intron 7 of the SMN2 pre-messenger ribonucleic</p><p>acid (pre-mRNA). By binding, the ASO displaces splicing factors, which normally suppress splicing. Displacement of these factors leads to retention of exon 7 in the SMN2 mRNA and hence when SMN2 mRNA is produced, it can be translated into the functional full length SMN protein.</p><p>&nbsp;</p><p>SMA is a progressive neuromuscular disease resulting from mutations in chromosome 5q in the</p><p>SMN1 gene. A second gene SMN2, located near SMN1, is responsible for a small amount of SMN</p><p>protein production. SMA is a clinical spectrum of disease with disease severity linked to fewer numbers of SMN2 gene copies and younger age of symptom onset.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em><u>Symptomatic patients </u></em></p><p><u>&nbsp;</u></p><p><em>Infantile onset</em></p><p>Study CS3B (ENDEAR) was a Phase 3, randomized, double-blind, sham-procedure controlled study conducted in 121 symptomatic infants &le; 7 months of age, diagnosed with SMA (symptom onset before 6 months of age). CS3B was designed to assess the effect of Spinraza on motor function and survival. Patients were randomized 2:1 to either Spinraza (as per the approved dosing regimen) or sham-control, with a length of treatment ranging from 6 to 442 days.</p><p>&nbsp;</p><p>The median age of onset of clinical signs and symptoms of SMA was 6.5 weeks and 8 weeks for Spinraza treated versus sham-control patients respectively, with 99% of patients having 2 copies of the SMN2 gene and therefore deemed most likely to develop Type I SMA. The median age when patients received their first dose was 164.5 days for treated patients, and 205 days for sham-control. Baseline disease characteristics were largely similar in the Spinraza treated patients and sham-control patients except that Spinraza treated patients at baseline had a higher percentage compared to</p><p>sham-control patients of paradoxical breathing (89% vs 66%), pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%) and requirement for respiratory support (26% vs 15%).</p><p><strong>&nbsp;</strong></p><p>At the final analysis, a statistically significant greater percentage of patients achieved the definition of a motor milestone responder in the Spinraza group (51%) compared to the sham-control</p><p>group (0%) (p&lt;0.0001). Time to death or permanent ventilation (&ge; 16 hours ventilation/day continuously for &gt; 21 days in the absence of an acute reversible event or tracheostomy) was assessed as the primary endpoint. Statistically significant effects on event-free survival, overall survival, the proportion of patients achieving the definition of a motor milestone responder, and the percentage of patients with at least a 4-point improvement from baseline in Children&rsquo;s Hospital of Philadelphia Infant Test for Neuromuscular Disease (CHOP INTEND) score were observed in patients in the Spinraza group compared to those in the sham-control group (Table 5).</p><p>&nbsp;</p><p>In the efficacy set, 18 patients (25%) in the Spinraza group and 12 patients (32%) in the sham-control group required permanent ventilation. Of these patients, 6 (33%) in the Spinraza group and 0 (0%) in the sham-control group met the protocol-defined criteria for a motor-milestone responder.</p><p>&nbsp;</p><p><strong>Table&nbsp;5: Primary and secondary endpoints at final analysis &ndash; Study&nbsp;CS3B</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Efficacy Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Spinraza treated Patients</strong></p></td><td style="vertical-align:top"><p><strong>Sham‑control Patients</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Survival</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Event-free survival<sup>2</sup></strong></p><p>Number of patients who died or received permanent ventilation</p><p>Hazard ratio (95% CI)</p><p>p-value<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31 (39%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>28 (68%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.53 (0.32 -0.89)</p><p>p = 0.0046</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Overall survival</strong><strong><sup>2</sup></strong></p><p>Number of patients who died</p><p>Hazard Ratio (95% CI)</p><p>p-value<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13 (16%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16 (39%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.37 (0.18 &ndash; 0.77)</p><p>p=0.0041</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Motor function</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Motor milestones</strong><strong><sup>3</sup></strong></p><p>Proportion achieving pre-defined motor milestone responder criteria (HINE section&nbsp;2)<sup>4,5</sup></p><p>Proportion at Day 183</p><p>Proportion at Day 302</p><p>Proportion at Day 394</p><p>Proportion with improvement in total motor milestone score<br />Proportion with worsening in total motor milestone score</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>37 (51%)<sup>1</sup></p><p>p&lt;0.0001</p><p>&nbsp;</p><p>41%</p><p>45%</p><p>54%</p><p>49 (67%)</p><p>&nbsp;</p><p>1 (1%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0 (0%)</p><p>&nbsp;</p><p>&nbsp;</p><p>5%</p><p>0%</p><p>0%</p><p>5 (14%)</p><p>&nbsp;</p><p>8 (22%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CHOP INTEND<sup>3</sup></strong></p><p>Proportion achieving a 4-point improvement</p><p>Proportion achieving a 4-point worsening</p><p>Proportion with any improvement</p><p>Proportion with any worsening</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>52 (71%)</p><p>p&lt;0.0001</p><p>2 (3%)</p><p>&nbsp;</p><p>53 (73%)</p><p>5 (7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1 (3%)</p><p>&nbsp;</p><p>17 (46%)</p><p>&nbsp;</p><p>1 (3%)</p><p>18 (49%)</p></td></tr></tbody></table><p><sup>1</sup>CS3B was stopped following positive statistical analysis on the primary endpoint at interim analysis (statistically significantly greater percentage of patients achieved the definition of a motor milestone responder in the Spinraza group&nbsp;(41%) compared to the sham‑control group&nbsp;(0%), p&lt;0.0001)</p><p><sup>2</sup>At the final analysis, event-free survival and overall survival were assessed using the Intent to Treat population (ITT Spinraza n=80; Sham‑control n=41).</p><p><sup>3</sup>At the final analysis, CHOP INTEND and motor milestone analyses were conducted using the Efficacy Set (Spinraza n=73; Sham‑control n=37).</p><p><sup>4</sup>Assessed at the later of Day&nbsp;183, Day&nbsp;302, and Day&nbsp;394 Study Visit</p><p><sup>5</sup>According to Hammersmith Infant Neurological Examination (HINE) section&nbsp;2: &ge;2&nbsp;point increase [or maximal score] in ability to kick, OR &ge;1&nbsp;point increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking, AND improvement in more categories of motor milestones than worsening, defined as a responder for this primary analysis.</p><p><sup>6</sup>Based on log-rank test stratified by disease duration</p><p>&nbsp;</p><p>The extent of improvement in CHOP INTEND is shown in Figure&nbsp;1 (change from baseline score for each subject).</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t75"
  coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
  filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_132" o:spid="_x0000_s1028" type="#_x0000_t75"
  style='position:absolute;margin-left:29.9pt;margin-top:33.5pt;width:368.65pt;
  height:220.5pt;z-index:251656704;visibility:visible;mso-wrap-style:square;
  mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
  mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:text;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
  mso-width-relative:page;mso-height-relative:page'>
  <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="491" height="294" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Figure&nbsp;1: Change in CHOP INTEND from Baseline to Later of Day&nbsp;183, Day&nbsp;302, and Day&nbsp;394 Study Visit &ndash; Endear Study /CS3B (Efficacy Set,&nbsp;ES)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>To allow for long term follow up of these patients, at the end of Study CS3B, 89 patients (Spinraza:&nbsp;n=65; sham‑control:&nbsp;n=24) enrolled in Study CS11 (SHINE). Study CS11 is an open label extension study for SMA patients who previously participated in the other Spinraza clinical studies.&nbsp; In Study CS11 all patients received Spinraza, with the length of treatment ranging from 65 to 592 days (median 289 days) at the time of interim analysis. Improvements in motor function were observed among patients continuing Spinraza from Study CS3B, as well as those who initiated Spinraza in Study CS11 (Figure 3), with the greatest benefit observed in those with earlier treatment initiation. Among patients without permanent ventilation at the baseline of Study CS11, a majority were alive and without permanent ventilation at the time of interim analysis.&nbsp;</p><p>&nbsp;</p><p>In patients randomized to Spinraza in Study CS3B and including the experience in Study CS11, the median time to death or permanent ventilation was 73 weeks.&nbsp; At the time of a Study CS11 interim analysis, 61 out of 65 patients (94%) were alive. Of the 45 patients who had not met the definition of permanent ventilation in Study&nbsp;CS3B, 38 patients (84%) were alive without permanent ventilation in Study CS11 at the time of interim analysis. Further improvement in mean total motor milestone (HINE-Section 2) (2.1; SD 4.36; n=22) and CHOP INTEND (4.68; SD 3.993, n=22) scores were observed from baseline to Study Day 304 in Study CS11.</p><p>&nbsp;</p><p>Patients who first initiated Spinraza treatment in Study CS11 (n=24; sham control in Study CS3B) were of a median age of 17.8 months (range 10 - 23 months) and had a mean CHOP INTEND score of 17.25 (range 2.0 - 46.0) at baseline in Study CS11. At the time of interim analysis, 22 out of 24 patients (92%) were alive. Of the twelve patients (50%) who had not met the definition of permanent ventilation in Study CS3B, 7 patients (58%) were alive without permanent ventilation in Study CS11. The median time to death or permanent ventilation was 50.9 weeks after initiation of Spinraza treatment in Study CS11. Improvement in mean total motor milestone (HINE-Section 2) (1.2; SD 1.8; n=12) and CHOP INTEND (3.58; SD 7.051, n=12) scores were observed from baseline to Study Day 304 in Study CS11.</p><p>&nbsp;</p><p>These results are supported by an open-label Phase 2 study in symptomatic patients diagnosed with</p><p>SMA (CS3A). Median age of onset of clinical signs and symptoms was 56 days and patients had</p><p>either 2 SMN2 gene copies (n=17) or 3 SMN2 gene copies (n=2) (SMN2 gene copy number unknown for 1 patient). Patients in this study were deemed most likely to develop Type I SMA. The median age at first dose was 162 days.</p><p>&nbsp;</p><p>The primary endpoint was the proportion of patients who improved in one or more categories in motor milestones (according to HINE section 2: &ge;2 point increase [or maximal score] in ability to kick or voluntary grasp OR &ge;1 point increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking). Twelve out of 20 patients (60%) in the study met the primary endpoint with improvement in mean motor milestone achievement over time. An improvement in mean CHOP INTEND score over time was observed from baseline to day 1072 (mean change 21.30). Overall, 11 out of 20 patients (55%) met the endpoint of an increase in total CHOP INTEND score of &ge;4 points as of the last study visit. Of the 20 subjects enrolled, 11 (55%) were alive and free of permanent ventilation at the last visit. Four patients met the criteria for permanent ventilation and five patients died during the study.</p><p>&nbsp;</p><p><em>Later onset</em></p><p>Study CS4 (CHERISH) was a Phase 3, randomised, double-blind, sham-procedure controlled study conducted in 126 symptomatic patients with later-onset SMA (symptom onset after 6 months of age). Patients were randomized 2:1 to either Spinraza (dosed with 3 loading doses and maintenance doses every 6 months) or sham-control, with a length of treatment ranging from 324 to 482 days. The median age at screening was 3 years, and the median age of onset of clinical signs and symptoms of SMA was 11 months. The majority of patients (88%) have 3 copies of the SMN2 gene (8% have</p><p>2 copies, 2% have 4 copies, and 2% have an unknown copy number). At baseline, patients had a mean</p><p>Hammersmith Functional Motor Scale Expanded (HFMSE) score of 21.6, a mean revised upper limb module (RULM) of 19.1, all had achieved independent sitting, and no patients had achieved independent walking. Patients in this study were deemed most likely to develop Type II or III SMA. Baseline disease characteristics were generally similar with the exception of an imbalance in the proportion of patients who had ever achieved the ability to stand without support (13% of patients in the Spinraza group and 29% in sham-control) or walk with support (24% of patients in the Spinraza group and 33% in sham-control).</p><p>&nbsp;</p><p>At the final analysis, a statistically significant improvement in HFMSE score from baseline to Month 15 was seen in the Spinraza group compared to the sham-control group (Table 6, Figure 2). The analysis was conducted in the ITT population (Spinraza: n=84; sham-control: n=42), and</p><p>post-baseline HFMSE data for patients without a Month 15 visit were imputed using the multiple</p><p>imputation method. An analysis of the subset of patients in the ITT population who had observed values at Month 15 demonstrated consistent, statistically significant results. Of those with observed values at Month 15, a higher proportion of Spinraza treated subjects had improvement (73% vs 41%, respectively) and a lower proportion of Spinraza treated subjects had worsening (23% vs 44%, respectively) in total HFMSE score compared to sham-control. Secondary endpoints including functional measures and WHO motor milestone achievement were formally statistically tested and are described in Table 6.</p><p>&nbsp;</p><p>Initiation of treatment sooner after symptom onset resulted in earlier and greater improvement in motor function than those with delayed treatment initiation; however, both groups experienced benefit compared to sham-control.</p><p>&nbsp;</p><p><strong>Table&nbsp;6: Primary and secondary endpoints at final analysis &ndash; Study&nbsp;CS4</strong><sup>1</sup></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Spinraza treated Patients </strong></p></td><td style="vertical-align:top"><p><strong>Sham‑control </strong><strong>Patients</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>HFMSE score</strong></p><p>Change from baseline in total HFMSE score at 15 months<sup>1,2,3</sup></p><p>&nbsp;</p><p>Proportion of patients who achieved at least a 3 point improvement from baseline to month 15<sup>2</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>3.9 (95% CI: 3.0, 4.9)</p><p>p=0.0000001</p><p>&nbsp;</p><p>56.8% (95% CI:45.6, 68.1)</p><p>P=0.0006<sup>5</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-1.0 (95% CI: -2.5, 0.5)</p><p>&nbsp;</p><p>&nbsp;</p><p>26.3% (95% CI: 12.4,40.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>RULM</strong></p><p>Mean change from baseline to month 15 in total RULM score<sup>2,3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.2(95% CI: 3.4, 5.0)</p><p>p=0.0000001<sup>6</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.5 (95% CI: -0.6, 1.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>WHO motor milestones</strong></p><p>Proportion of patients who achieved new motor milestones at 15 months<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19.7% (95% CI: 10.9,</p><p>31.3)</p><p>p=0.0811</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.9% (95% CI: 0.7,</p><p>19.7)</p><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>CS4 was stopped following positive statistical analysis on the primary endpoint at interim analysis (statistically significant improvement from baseline HFMSE score was observed in Spinraza treated patients compared to the sham‑control patients (Spinraza vs. sham-control: 4.0 vs. -1.9; p=0.0000002))</p><p><sup>2</sup> Assessed using the Intent to Treat population (Spinraza n=84; Sham-control n=42); data for patients without a Month 15 visit were imputed using the multiple imputation method</p><p><sup>3</sup>Least squares mean</p><p><sup>4</sup> Assessed using the Month 15 Efficacy Set (Spinraza n=66; Sham control n=34); analyses are based on</p><p>imputed data when there are missing data.</p><p><sup>5 </sup>Based on logistic regression with treatment effect and adjustment for each subject&#39;s age at screening and HFMSE score at baseline</p><p><sup>6</sup>Nominal p value</p><p><sup>&nbsp;</sup></p><p><strong>Figure 2: Mean change from baseline in HFMSE score over time at final analysis (ITT) &ndash;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Picture_x0020_142" o:spid="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  margin-left:46.55pt;margin-top:26pt;width:353.55pt;height:262.8pt;z-index:251657728;
  visibility:visible;mso-wrap-style:square;mso-width-percent:0;
  mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
  mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page'>
  <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
  <w:wrap type="topAndBottom"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="471" height="350" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Study&nbsp;CS4 <sup>1,2</sup></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Upon completion of Study CS4 (CHERISH) 125 patients enrolled in Study CS11 (SHINE), where all patients received Spinraza. The length of treatment ranged from 74 to 474 days (median 250 days) at the time of the interim analysis. A majority of Spinraza treated patients experienced stabilization or improvement in motor function, with the greatest benefit observed in those with earlier treatment initiation.</p><p>&nbsp;</p><p>Of patients who initiated Spinraza treatment in Study CS4 (n=39), stabilization or additional improvements in mean HFMSE (0.2; SD 3.06) and RULM (0.7; SD 2.69) scores were observed from baseline to Study Day 265 in Study CS11.</p><p>&nbsp;</p><p>Patients who initiated Spinraza treatment in Study CS11 (n=20) had a median age of 4.0 years (range 3 - 8 years). Of these patients, stabilization or improvement in mean HFMSE (1.4; SD 4.02) and RULM (2.1; SD 2.56) scores were observed from baseline to Study Day 265 in Study CS11.</p><p>&nbsp;</p><p>These results are supported by 2 open label studies (study CS2 and study CS12). The analysis included 28 patients who received their first dose in study CS2, and then transferred to the extension phase, study CS12. The studies enrolled patients who were between 2 to 15 years of age at first dose. Of the 28 patients, 3 were at least 18 years of age at their last study visit. 1 out of 28 patients had</p><p>2 SMN2 gene copies, 21 had 3 copies, and 6 had 4 copies.</p><p>&nbsp;</p><p>Patients were assessed over a 3 year treatment period. A sustained improvement was seen in patients with Type II SMA who experienced a mean improvement from baseline HFMSE score of 5.1</p><p>(SD 4.05, n=11) at Day 253, and 9.1(SD 6.61, n=9) at Day 1050.The mean total score was 26.4 (SD 11.91) at Day 253 and 31.3 (SD 13.02) at Day 1050, no plateau was observed. Patients with</p><p>Type III SMA demonstrated a mean improvement from baseline HFMSE score of 1.3 (SD 1.87, n=16) at Day 253 and 1.2 (SD 4.64, n=11) at Day 1050. The mean total score was 49.8 (SD 12.46) at Day 253 and 52.6 (SD 12.78) at 1050 days.</p><p>&nbsp;</p><p>In patients with Type II SMA the Upper Limb Module test was conducted with mean improvement of</p><p>1.9 (SD 2.68, n=11) at Day 253 and 3.5 (SD 3.32, n=9) at Day 1050. The mean total score was13.8 (SD 3.09) at Day 253 and 15.7 (SD 1.92) at Day 1050.</p><p>&nbsp;</p><p>The 6MWT (six-minute walk test) was conducted for ambulatory patients only. In these patients, a mean improvement of 28.6 meters (SD 47.22, n=12) at Day 253 and 86.5 metres (SD 40.58, n=8) at Day 1050. The mean 6MWT distance was 278.5 meters (SD 206.46) at Day 253 and 333.6 metres (SD 176.47) at Day 1050. Two previously non-independent ambulatory patients (Type III) achieved independent walking, and one non-ambulatory patient (Type II) achieved independent walking.</p><p>&nbsp;</p><p>An additional clinical study, CS7 (EMBRACE) was opened for patients not eligible for participation in Study CS3B or Study CS4 due to screening age or SMN2 copy number. CS7 is a phase 2, randomized, double-blind, sham-procedure study in symptomatic patients diagnosed with infantile-onset SMA (&le;6 months) or later-onset SMA (&gt;6 months) and 2&nbsp;or&nbsp;3&nbsp;copies of SMN2 (Part 1), followed by a long-term open label extension phase (Part 2). In Part 1 of the study, patients were followed for a median of 302 days.</p><p>&nbsp;</p><p>All patients who received Spinraza were alive as of the early termination of Part 1, however, one patient in the control arm died at Study Day 289. In addition, no patients in the Spinraza or sham-control group required the use of permanent ventilation. Of the 13 patients with infantile-onset SMA, 7 of out 9 patients (78%; 95%CI: 45, 94) in the Spinraza group and 0 out of 4 patients (0%; 95%CI: 0, 60) in the sham group met the criteria for motor milestone response (according to HINE section&nbsp;2: &ge;2 point increase [or&nbsp;maximal&nbsp;score] in ability to kick OR &ge;1&nbsp;point increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking and improvement in more categories of motor milestones than worsening). Of the 8 patients with later-onset SMA, 4 out of 5 patients (80%; 95% CI: 38, 96) in the Spinraza group and 2 out of 3 (67%; 95% CI: 21, 94) in the sham-control group met this definition of response.</p><p>&nbsp;</p><p><em><u>Adult </u></em></p><p><u>&nbsp;</u></p><p><u>Real world clinical findings support the effectiveness of nusinersen to stabilize or improve motor function in some SMA adult Type II and III patients. </u></p><p><u>By month 14 of nusinersen treatment, the number of patients with a clinically meaningful improvement from baseline on HFMSE (&ge; 3 points) was 53 out of 129 patients, the number of patients with clinically meaningful improvement on the RULM (&ge; 2 points) was 28 out of 70 and among walkers 25 out of 49 for the 6MWT (&ge; 30 meters).</u></p><p><u>&nbsp;</u></p><p><u>The safety data in the adult population are consistent with the known safety profile of nusinersen and with co-morbidities associated with the underlying disease of SMA.</u></p><p><u>&nbsp;</u></p><p><em><u>Pre-symptomatic infants</u></em></p><p><em><u>&nbsp;</u></em></p><p>Study CS5 (NURTURE) is an open‑label study in pre‑symptomatic infants genetically diagnosed with SMA, who were enrolled at 6&nbsp;weeks of age or younger. Patients in this study were deemed most likely to develop Type&nbsp;I or II&nbsp;SMA. Median age at first dose was 22&nbsp;days. &nbsp;</p><p>&nbsp;</p><p>An interim analysis was conducted when patients had been on study for median of 27.1 months (15.1 -35.5 months) and were of a median age at last visit of 26.0 months (14.0 -34.3 months). At the interim analysis, all 25 patients (2 SMN2 gene copies, n=15; 3 SMN2 gene copies, n=10) were alive without permanent ventilation. The primary endpoint, time to death or respiratory intervention (defined as invasive or non-invasive ventilation for &ge;6&nbsp;hours/day continuously for &ge;7&nbsp;consecutive days OR tracheostomy), could not be estimated as there were too few events. Four patients (2 SMN2 copies) required respiratory intervention &gt;6 hours/day continuously for &ge;7 days, all of whom initiated ventilatory support during an acute reversible illness.</p><p>&nbsp;</p><p>Patients achieved milestones unexpected in Type I or II SMA and more consistent with normal development. At the interim analysis, &nbsp;all 25 (100%) patients had achieved the WHO motor milestone of sitting without support, 22 (88%) patients were walking with assistance. Among patients older than the WHO defined window for expected age of achievement (95<sup>th</sup> percentile), 17 of 22 (77%) had achieved walking alone.&nbsp; The mean CHOP INTEND score at last assessment was 61.0 (46 - 64) amongst patients with 2 SMN2 copies and 62.6 (58 - 64) amongst those with 3 SMN2 copies. All patients had the ability to suck and swallow at last assessment, with 22 (88%) infants achieving a maximal score on the HINE Section 1.</p><p>&nbsp;</p><p>The proportion of patients developing clinically manifested SMA was assessed amongst patients who reached the Day&nbsp;700 visit at the interim analysis&nbsp;(n=16). The protocol‑defined criteria for clinically manifested SMA included age‑adjusted weight below the fifth WHO percentile, a decrease of 2&nbsp;or more major weight growth curve percentiles, the placement of a percutaneous gastric tube, and/or the inability to achieve expected age‑appropriate WHO milestones (sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone and walking alone). At day 700, 7 out of 11 patients (64%) with 2 SMN2 gene copies and 0 out of 5 patients (0%) with 3 SMN2 copies, met the protocol-defined criteria of clinically manifested SMA, however, these patients were gaining weight and achieving</p><p>WHO milestones, inconsistent with Type I SMA.</p><p>&nbsp;</p><p>A comparison of motor milestone achievement among the patients with symptomatic infantile‑onset SMA and pre‑symptomatic SMA is shown in Figure 3.</p><p>&nbsp;</p><p><strong>Figure 3: Change in HINE Motor Milestones versus Study days for Study&nbsp;CS3B (treated and sham‑control), CS3A, CS5 and CS11</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_195" o:spid="_x0000_s1026"
 type="#_x0000_t75" style='position:absolute;margin-left:27.05pt;margin-top:-6.95pt;
 width:399.4pt;height:263.85pt;z-index:251658752;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page'>
 <v:imagedata src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
  o:title="" croptop="4774f" cropbottom="3038f"/>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="533" height="352" src="file:///C:/Users/ABDULL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single- and multiple-dose pharmacokinetics (PK) of nusinersen, administered via intrathecal injection, were determined in paediatric patients diagnosed with SMA.</p><p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>Intrathecal injection of nusinersen into the CSF allows nusinersen to be fully available for distribution from the CSF to the target central nervous system (CNS) tissues. Mean CSF trough concentrations of nusinersen accumulated approximately 1.4‑ to 3‑fold after multiple loading and maintenance doses,and reached a steady state within approximately 24&nbsp;months. Following intrathecal administration trough plasma concentrations of nusinersen were relatively low compared to the trough CSF concentration. Median plasma T<sub>max</sub> values ranged from 1.7&nbsp;to&nbsp;6.0 hours. Mean plasma C<sub>max</sub> and AUC values increased approximately dose proportionally over the evaluated dose range. There is no accumulation in plasma exposure measures (C<sub>max</sub> and AUC) after multiple doses.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Autopsy data from patients (n=3) show that nusinersen administered intrathecally is broadly distributed within the CNS achieving therapeutic levels in the target spinal cord tissues. Presence of nusinersen was also demonstrated in neurons and other cell types in the spinal cord and brain, and peripheral tissues such as skeletal muscle, liver, and kidney.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Nusinersen is metabolized slowly and predominantly via exonuclease (3&rsquo;- and 5&rsquo;) -mediated hydrolysis and is not a substrate for, or inhibitor or inducer of CYP450 enzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The mean terminal elimination half-life in CSF is estimated at 135 to 177 days. The primary route of elimination is expected via urinary excretion of nusinersen and its metabolites.</p><p>&nbsp;</p><p><u>Interactions</u></p><p><u>&nbsp;</u></p><p><em>In vitro</em> studies indicated that nusinersen is not an inducer or inhibitor of CYP450‑mediated oxidative metabolism and therefore should not interfere with other medicinal products for these metabolic pathways. Nusinersen is not a substrate or inhibitor of human BCRP, P‑gp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, or BSEP transporters.</p><p>&nbsp;</p><p><u>Characteristics in specific patient populations</u></p><p><u>&nbsp;</u></p><p><em>Renal and hepatic impairment</em></p><p>The pharmacokinetics of nusinersen in patients with renal or hepatic impairment has not been studied. The effect of hepatic or renal insufficiency as covariates could not be thoroughly evaluated in the population PK model given the rarity of patients displaying clinically relevant liver or kidney</p><p>insufficiencies. Population PK analyses revealed no apparent correlation between hepatic and renal clinical chemistry markers and inter-subject variability.</p><p>&nbsp;</p><p><em>Race</em></p><p>The majority of patients studied were Caucasian. The population PK analysis suggests that race is unlikely to affect the PK of nusinersen.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis</u></p><p><u>&nbsp;</u></p><p>Long‑term studies in animals to evaluate the carcinogenic potential of nusinersen have not been performed.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p><u>&nbsp;</u></p><p>Nusinersen demonstrated no evidence of genotoxicity.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p><u>&nbsp;</u></p><p>Reproductive toxicology studies were conducted using subcutaneous administration of nusinersen in mice and rabbits. No impact on male or female fertility, or embryo-foetal development, or</p><p>pre/post-natal development was observed.</p><p>&nbsp;</p><p><u>Toxicology</u></p><p><u>&nbsp;</u></p><p>In repeat-dose toxicity studies (14-weeks and 53-weeks) of intrathecal administration to juvenile cynomolgus monkeys, nusinersen was well tolerated. The exception was an acute, transient deficit in lower spinal reflexes which occurred at the highest dose levels in each study (3 or 4 mg per dose; equivalent to 30 or 40 mg per intrathecal dose in patients). These effects were observed within several hours post-dose and generally resolved within 48 hours.</p><p>&nbsp;</p><p>In the 53-week intrathecal dosing study in cynomolgus monkeys no toxicity effects were seen at levels up to 14-fold the recommended annual clinical maintenance dose.</p><p><u>&nbsp;</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium dihydrogen phosphate dihydrate</p><p>Disodium phosphate</p><p>Sodium chloride</p><p>Potassium chloride</p><p>Calcium chloride dihydrate</p><p>Magnesium chloride hexahydrate</p><p>Sodium hydroxide (for pH adjustment)</p><p>Hydrochloric acid (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C ‑ 8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>If no refrigeration is available, Spinraza may be stored in its original carton, protected from light at or below 30&deg;C for up to 14&nbsp;days.</p><p>&nbsp;</p><p>Prior to administration, unopened vials of Spinraza can be removed from and returned to the refrigerator if necessary. If removed from the original carton, the total combined time out of refrigeration should not exceed 30 hours, at a temperature that does not exceed 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5&nbsp;ml in a Type&nbsp;I glass vial with bromobutyl rubber stopper and an aluminium over‑seal and plastic cap.</p><p>Pack size of one&nbsp;vial per carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only.</p><p>&nbsp;</p><p><u>Instructions for</u> <u>preparation of the medicinal product before administration</u></p><p><u>&nbsp;</u></p><p>1. The Spinraza vial should be inspected for particles prior to administration. If particles are observed and/or the liquid in the vial is not clear and colourless, the vial must not be used.</p><p>2. Aseptic technique should be used when preparing Spinraza solution for intrathecal administration.</p><p>3. The vial should be taken out of the refrigerator and allowed to warm to room temperature (25&deg;C)</p><p>without using external heat sources, prior to administration.</p><p>4. If the vial remains unopened and the solution is not used, it should be returned back to the refrigerator (see section 6.4).</p><p>5. Just prior to administration, remove the plastic cap and insert the syringe needle into the vial through the centre of the over-seal to remove the appropriate volume. Spinraza must not be diluted. The use of external filters is not required.</p><p>6. Once drawn into the syringe, if the solution is not used within 6 hours, it must be discarded.</p><p>7. Any unused product or waste material must be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>